Mylan Sees Nebivolol Launch For Hypertension If Heart Failure Use Is Delayed
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Mylan would launch nebivolol with a hypertension indication soon after approval if it appears FDA consent for a supplemental indication in congestive heart failure would be far off, the company said